Independent clinical studies and research demonstrate benefits across numerous health and wellness categories including lowering cholesterol, reducing hyperglycemia and improving insulin levels and insulin sensitivity
SCOTTSDALE, Ariz., March 2, 2015 /PRNewswire/ — RiceBran Technologies (NASDAQ: RIBT and RIBTW) (“RBT”), a global leader in the production and marketing of value added products derived from rice bran, today announced the release of a claims substantiation analysis of the health benefits of RBT’s proprietary rice bran based ingredients conducted by Medicus Research.
RBT contracted Medicus Research, the premier contract research organization for the Dietary Supplement, Functional Foods and Botanical Drug industries, to perform a comprehensive analysis of independent studies conducted on behalf of RBT to substantiate numerous important health claims for its proprietary and process patented rice bran derivatives and products.
The research from Medicus substantiates that RBT’s RiBran and RiSolubles® products reduce hyperglycemia; improves insulin levels and insulin sensitivity; and increases adiponectin levels. The research also cites scientific evidence indicating that the Company’s RiFiber product reduces total cholesterol, LDL cholesterol and triglycerides; reduces absorption of cholesterol; and reduces plasma lipid and lipoprotein cholesterol.
The full report as well as links to clinical study findings can be found on RBT’s home page at www.ricebrantech.com.
W. John Short, CEO & President of RBT commented, “As the consumer package goods industry focuses billions of dollars on healthy whole food nutrition, the ability to provide ingredients that can result in important front of label claims for these new products differentiates RBT from our competitors. Medicus Research is widely considered to be the leading provider of research and clinical trials for healthy, natural products and functional foods. We are excited that the team at Medicus has substantiated the health benefits of our rice bran based products. We plan to pursue additional studies with Medicus going forward.”
Dr. Jay Udani, co-founder and CEO of Medicus Research noted, “RiceBran Technologies proprietary ingredients and the active components of these ingredients have been the subject of numerous studies which, when the evidence is combined, appear to be able to substantiate claims related to the management of healthy lipids, glucose, and insulin. We look forward to working with RBT on additional projects in the future.”
About Medicus Research
Medicus Research is the internationally renowned contract research organization specializing in the study of dietary supplements, functional foods, medical foods, botanical drugs and cosmeceuticals. The California-based CRO was founded 15 years ago by Dr. Jay Udani. As a board-certified internist at Cedars-Sinai Medical Center in Beverly Hills, Dr. Udani was among the first physicians in America to become a certified physician investigator for clinical trials. He was passionate about the study of natural health products as an alternative to traditional pharmaceuticals. Today, Dr. Udani’s company is considered the leader in this industry. Medicus Research has designed, executed and analyzed more than 200 Phase I – IV clinical trials. The company designs its clinical trials to guarantee that its studies are structure/function compliant and follow strict guidelines issued by FTC, FDA, and EFSA for subject population and endpoint selection. Medicus Research has established GCP and FDA compliant SOPs, internal QA processes, and proprietary management technology systems which ensure the highest quality for all aspects of the study process.
About RiceBran Technologies
RiceBran Technologies is a human food ingredient and functional food company focused on the procurement, bio-refining and marketing of numerous products derived from rice bran. RiceBran Technologies has proprietary and patented intellectual property that allows us to convert rice bran, one of the world’s most underutilized food sources, into a number of highly nutritious human food ingredient and animal nutrition products. Our target markets are human food ingredients and animal nutrition manufacturers and retailers, as well as natural food, functional food and nutraceutical supplement manufacturers and retailers, both domestically and internationally. More information can be found in our filings with the SEC and by visiting our website at www.ricebrantech.com.
This release contains forward-looking statements, including, but not limited to, statements about RiceBran Technologies’ expectations regarding introduction of new products for the craft brewing industry. These statements are made based upon current expectations that are subject to known and unknown risks and uncertainties. RiceBran Technologies does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in RiceBran Technologies’ filings with the Securities and Exchange Commission, including its most recent periodic reports.
Investor Relations Contact:
Ascendant Partners, LLC